Company intelligence / Profile preview

Breath Diagnostics

Louisville, Kentucky, United Statesbreathdiagnostics.com ↗

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

Breath Diagnostics' OneBreath™ platform has demonstrated high accuracy in early lung cancer detection, with clinical trials showing 94% sensitivity and 85–86% specificity across more than 800 patients. The device is non-invasive, cost-effective, and designed for broad accessibility in clinics and community settings. No commercial launch or regulatory approval is indicated as of June 2025.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy (breath analysis)
Industry: Metabolite Diagnostics

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Breath Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Breath Diagnostics.

Explore the full profile